CIK 0001279704 · Non-accelerated filer<br>Smaller reporting company
Cellectar Biosciences, Inc.
Sign in to watch- Ticker
- CLRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043321804
- Phone
- (608) 441-8120
- Business address
- 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
- Former names
- NOVELOS THERAPEUTICS, INC., COMMON HORIZONS INC
- 4 Open-market buy Chief Financial Officer bought 7,407 shares at $1.35 ($9,999)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 18,000 shares at $1.08 ($19,438)
- 4 Open-market buy Chief Financial Officer bought 4,348 shares at $1.15 ($4,978)
- 4 Open-market buy Chief Business Officer bought 65,218 shares at $1.15 ($74,675)
- 4 Open-market buy President and CEO bought 21,740 shares at $1.15 ($24,892)
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Grant or award Chief Financial Officer acquired 10,000 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 40,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 100,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
Page 5 of 11 · 211 filings